2021年12月13日 · NOX-A12（olaptesed pegol）是由NOXXON Pharma开发的一款靶向基质细胞衍生因子-1（SDF-1，又称趋化因子CXCL12）的聚乙二醇化的核酸适配体药物。 该药物是利用NOXXON的专有技术Spiegelmers生产的化合物（L-立体异构体）。

NOX-A12 (olaptesed pegol) is an intravenously administered, PEGylated L-stereoisomer RNA aptamer that targets CXCL12 (C-X-C Chemokine Ligand 12), a key chemokine (signaling) protein. Chemokines can be thought of as road signs in the body that direct movement of cells that encounter them.

2024年5月28日 · Targeting CXCL12 with the pegylated L-RNA aptamer olaptesed pegol (NOX-A12) was highly effective in an autochthonous rat brain tumor model mimicking a highly treatment-refractory GBM 32. In this...

Olaptesed pegol (NOX-A12) is a pegylated structured L-oligoribonucleotide that binds and neutralizes CXCL12, a chemokine tightly regulating the life cycle of chronic lymphocytic leukemia cells. The resulting inhibition of CXCR4 and CXCR7 signaling reduces the protective activity of the bone marrow a …

NOX-A12(olaptesed pegol)是一种静脉注射的、PEG化的L-stereoisomer RNA适配体，针对CXCL12，一种关键的化学因子(信号传导)蛋白。 2014年， 美国食品和药物管理局 授予NOX-A12孤儿药称号，与放射治疗联合用于胶质母细胞瘤患者。

2017年1月11日 · Olaptesed pegol (olaptesed, NOX-A12) is a pegylated l -oligoribonucleotide that binds and neutralizes CXCL12, a chemokine which signals through CXCR4 and CXCR7 regulating a...

2023年11月2日 · NOX-A12(olaptesed pegol)是针对关键的趋化因子蛋白CXCL12而开发的。 在癌症中，这种趋化因子蛋白是肿瘤细胞和环境之间的沟通桥梁，已知它鼓励肿瘤增殖，形成新的血管和转移，并减少细胞死亡。

2019年5月26日 · Background: NOX-A12 is an inhibitor of the chemokine CXCL12 which prevents receptor engagement and blocks the formation of chemotactic CXCL12 concentration gradients. The OPERA study (NCT03168139) is a Phase 1/2 study to evaluate pharmacodynamic effects and safety of monotherapy with NOX-A12 as well as safety and efficacy of a combination with ...

2014年2月13日 · NOX-A12, an RNA oligonucleotide in L-configuration (Spiegelmer) that binds and neutralizes CXCL12, was developed for interference with CXCL12 in the tumor microenvironment and for cell mobilization. Here, we examined effects of NOX-A12 on CLL cell migration and drug sensitivity.

2014年2月13日 · Schematic overview of NOX-A12 mechanism of action in CLL. NOX-A12 detaches CXCL12 from the surface of bone marrow stromal cells (BMSCs), thereby neutralizing the chemokine. As a consequence, NOX-A12 mobilizes CLL cells from their protective microenvironment, inducing apoptosis and chemosensitization on leukemic cells. …